Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

The identification of biomarkers predicting the burden of brain alpha-synuclein (α-syn) pathology in vivo represents a research priority in Lewy body disease (LBD). Recently, some kinetic parameters of seed amplification assays (SAAs) for α-syn showed associations with measures of clinical progression. However, preanalytical and analytical factors significantly affect these parameters, reducing reproducibility. The Endpoint Dilution (ED) SAA Real-time Quaking-induced Conversion (RT-QuIC) is emerging as an alternative, more accurate tool for seed quantification. Still, the approach needs validation in large patient cohorts. We applied the ED RT-QuIC to postmortem ventricular cerebrospinal fluid (CSF) samples from 357 brain donors, including 168 who showed LBD at neuropathologic examination. We estimated the seeding dose, yielding positive responses in 50% of replicate reactions (SD50), using the midSIN algorithm and correlated these values with postmortem synuclein pathology burden and clinical severity measures. LBD was staged through the Unified Staging System for Lewy Body Disorders and the Lewy pathology consensus criteria. The SD50 values (expressed in log 10 SD/ml) differed significantly among participants at different LBD stages ( p < 0.0001), with those at a neocortical stage demonstrating higher values than those at a brainstem-predominant stage ( p < 0.0001). The SD50 values were significantly associated with the LBD load evaluated through immunohistochemistry (Rho = 0.62, p < 0.0001). Participants showing higher SD50 values performed worse at the last available scores on clinical scales evaluating motor (Rho = 0.33, p < 0.0001) and olfactory functions (Rho = − 0.33, p < 0.0001). The SD50 scores accurately distinguished neocortical LBD participants from those at lower stages (area under the curve, 0.86; 95% confidence interval, 0.79–0.92). The CSF ED RT-QuIC measure of α-syn seeds correlated significantly with LBD burden and clinical severity scores. These findings validate the CSF ED RT-QuIC as a quantitative assay for misfolded brain α-syn in LBD. This novel approach may be clinically applied to identify individuals at different stages of LBD pathology in research settings.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mastrangelo, A., Caldera, S., Mastenbroek, S. E., Vittoriosi, E., Janelidze, S., Serrano, G. E., et al. (2025). Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathologica. https://doi.org/10.1007/s00401-025-02904-4

Vancouver

Mastrangelo A, Caldera S, Mastenbroek SE, Vittoriosi E, Janelidze S, Serrano GE, et al. Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathologica. 2025. doi:10.1007/s00401-025-02904-4. PMID: 40549179.

BibTeX

@article{mastrangelo2025-40549179,
  author  = {Mastrangelo, Andrea and Caldera, Serena and Mastenbroek, Sophie E and Vittoriosi, Erica and Janelidze, Shorena and Serrano, Geidy E. and Atri, Alireza and Shill, Holly A. and others},
  title   = {{Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants}},
  journal = {Acta Neuropathologica},
  year    = {2025},
  doi     = {10.1007/s00401-025-02904-4},
  pmid    = {40549179},
  url     = {https://doi.org/10.1007/s00401-025-02904-4}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study applied an endpoint dilution RT-QuIC assay to postmortem cerebrospinal fluid and found that seeding dose values differed significantly among Lewy body disease stages and correlated with pathology burden. It supports a biomarker for Lewy body pathology but does not offer a treatment or cure.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Acta Neuropathologica)
Journal's citation record 3 / 4 Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 15 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Piero Parchi: h-index 84 (OpenAlex, whole career)
Institution's track record 1 / 3 Lund University: institution h-index 1,119 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 10 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40549179)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Lewy body dementia

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →